ARHGAPs, or Rho GTPase activating proteins, are a family of proteins that regulate Rho GTPases, which are critical for cell signaling. Rho GTPases are molecular switches that control various cellular processes, including cytoskeletal dynamics, cell migration, and proliferation. They cycle between an active GTP-bound state and an inactive GDP-bound state. ARHGAP proteins facilitate the transition of Rho GTPases from their active to inactive form by increasing their intrinsic GTPase activity. This regulation is crucial for maintaining cellular homeostasis and responding to extracellular signals. Dysregulation of Rho GTPase signaling can lead to various diseases, including cancer, underscoring the importance of ARHGAPs in cell biology.
Targeting ARHGAPs for disruption or inhibition has emerged as a potential strategy in diseases where Rho GTPase signaling is aberrant. Inhibiting specific ARHGAPs can modulate the activity of Rho GTPases, thereby altering cellular behaviors that contribute to disease progression. For example, in cancer, targeting ARHGAPs could disrupt tumor cell migration and invasion. However, this approach requires careful consideration of the specific ARHGAP and tissue context, as Rho GTPases play diverse roles in different cell types. Additionally, targeting ARHGAPs poses challenges in achieving specificity and avoiding unintended effects on normal cellular functions.
VER TAMBIÉN ....
| Nombre del producto | NÚMERO DE CAS # | Número de catálogo | Cantidad | Precio | MENCIONES | Clasificación |
|---|---|---|---|---|---|---|
Fasudil, Monohydrochloride Salt | 105628-07-7 | sc-203418 sc-203418A sc-203418B sc-203418C sc-203418D sc-203418E sc-203418F | 10 mg 50 mg 250 mg 1 g 2 g 5 g 10 g | $18.00 $33.00 $87.00 $168.00 $253.00 $496.00 $910.00 | 5 | |
Inhibidor de ROCK que puede estabilizar la actividad de ARHGAP a través de la disminución de la retroalimentación de la vía. | ||||||
H-1152 dihydrochloride | 451462-58-1 | sc-203592 sc-203592A | 1 mg 5 mg | $104.00 $364.00 | 7 | |
Otro inhibidor de la Rho quinasa que podría influir potencialmente en las acciones reguladoras de ARHGAP39 sobre las Rho GTPasas. | ||||||
EHT 1864 | 754240-09-0 | sc-361175 sc-361175A | 10 mg 50 mg | $213.00 $889.00 | 12 | |
Inhibidor de Rac1 que podría reducir la señalización mediada por ARHGAP mediante la estabilización de Rac1 inactivo. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Inhibe Trio, un GEF, modificando potencialmente la actividad GTPasa mediada por ARHGAP. | ||||||
Rhosin | 1173671-63-0 | sc-507401 | 25 mg | $555.00 | ||
Inhibe selectivamente la unión de RhoA a GEF, posiblemente modulando los efectos reguladores de ARHGAP. | ||||||
Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor Inhibidor | 509093-47-4 | sc-204013 | 5 mg | $163.00 | 2 | |
inhibidor específico de la actividad Cdc42, podría ajustar el impacto regulador de ARHGAP. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
inhibidor de Cdc42, que podría afectar a los procesos aguas abajo regulados por ARHGAP. | ||||||
PAC 1 | 315183-21-2 | sc-203174 sc-203174A | 10 mg 50 mg | $132.00 $536.00 | 1 | |
Inhibe las citohesinas, pudiendo influir indirectamente en la actividad de ARHGAP. | ||||||
RKI-1447 | 1342278-01-6 | sc-472590 | 1 mg | $330.00 | ||
Inhibe la interacción entre JMY y RhoA, influyendo así indirectamente en la actividad de ARHGAP dentro de la vía Rho GTPasa. | ||||||